Leo A Hardegger Selected Research

Intravitreal Injections

1/2018

The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Leo A Hardegger Research Topics

Disease

1	Macular Degeneration (Age-Related Maculopathy) 01/2018
1	Choroidal Neovascularization 01/2018

Drug/Important Bio-Agent (IBA)

1	acrizanibIBA 01/2018
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018

Therapy/Procedure

1	Topical Administration 01/2018
1	Therapeutics 01/2018
1	Intravitreal Injections 01/2018